Shulph Ink
New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies
New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies
YOU SAVE £15.81
- Condition: Brand new
- UK Delivery times: Usually arrives within 2 - 3 working days
- UK Shipping: Fee starts at £2.39. Subject to product weight & dimension
Couldn't load pickup availability
Excellent- More about New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies
New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies discusses the resistance of human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies and the use of targeted sensitizing agents to reverse resistance. It is a valuable resource for cancer researchers, oncologists, pharmacologists, and other members of the biomedical field interested in fighting cancer resistance to anti-CD20 antibodies.
Format: Hardback
Length: 250 pages
Publication date: 01 March 2024
Publisher: Elsevier Science Publishing Co Inc
New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies offers comprehensive and up-to-date insights into the resistance exhibited by diverse human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It delves into the description of various targeted sensitizing agents that possess the potential to reverse innate or acquired resistance when combined with various FDA-approved anti-CD20 antibodies.
While the treatment of lymphomas/leukemias with anti-CD20 antibodies has yielded significant clinical responses in numerous cases, it is important to note that a subset of cancer patients initially failed to respond, and even among those who did respond, resistance to subsequent treatments emerged. Consequently, the exploration of various immunosensitizing agents aimed at targeting resistant factors has gained attention, with this book providing in-depth discussions on each of them. These agents include Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors.
This book serves as a valuable resource for cancer researchers, oncologists, pharmacologists, and individuals engaged in the field of biomedical research, with a particular interest in combating cancer resistance to anti-CD20 antibodies. By exploring these novel combination approaches, researchers and practitioners can further enhance the efficacy of Rituximab-based lymphoma therapies and improve patient outcomes.
Dimension: 234 x 191 (mm)
ISBN-13: 9780128164075
This item can be found in:
UK and International shipping information
UK and International shipping information
UK Delivery and returns information:
- Delivery within 2 - 3 days when ordering in the UK.
- Shipping fee for UK customers from £2.39. Fully tracked shipping service available.
- Returns policy: Return within 30 days of receipt for full refund.
International deliveries:
Shulph Ink now ships to Australia, Belgium, Canada, France, Germany, Ireland, Italy, India, Luxembourg Saudi Arabia, Singapore, Spain, Netherlands, New Zealand, United Arab Emirates, United States of America.
- Delivery times: within 5 - 10 days for international orders.
- Shipping fee: charges vary for overseas orders. Only tracked services are available for most international orders. Some countries have untracked shipping options.
- Customs charges: If ordering to addresses outside the United Kingdom, you may or may not incur additional customs and duties fees during local delivery.
